Experimental drug given before surgery shows promise against rare cancer
NCT ID NCT04973683
Summary
This early-stage trial is testing whether giving the drug AL101 before standard surgery can help control adenoid cystic carcinoma, a rare type of cancer. The study involves 14 patients whose cancer has a specific genetic feature called NOTCH activation. Researchers want to see if AL101 is safe when given for 6-8 weeks before surgery and if it reduces cancer activity in the tumor.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADENOID CYSTIC CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.